Zenas BioPharma (ZBIO) Share-based Compensation (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Share-based Compensation of $80.3 million for Q1 2026, up 1390.9% year-over-year from $5.4 million in Q1 2025, and up 959.37% quarter-over-quarter from $7.6 million in Q4 2025.
Zenas BioPharma (ZBIO) Share-based Compensation (2023 - 2026) Analysis & Trends
Zenas BioPharma's Share-based Compensation history runs 4 years deep, the most recent figure standing at $80.3 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 1390.9% year-over-year to $80.3 million; the TTM figure through Mar 2026 stood at $80.3 million (up 1349.72% YoY), while the FY2025 annual figure was $83.7 million, up 12.5% from the prior year.
- Share-based Compensation for Q1 2026 stood at $80.3 million, up from $7.6 million in the prior quarter.
- The five-year high for Share-based Compensation was $81.2 million in Q3 2025, with the low at -$4.2 million in Q4 2024.
- The 4-year median for Share-based Compensation is $2.8 million (2024), against an average of $16.7 million.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation slumped 472.33% in 2024, then surged 2756.14% in 2025.
- Zenas BioPharma's Share-based Compensation stood at $1.1 million in 2023, then plunged by 472.33% to -$4.2 million in 2024, then soared by 279.37% to $7.6 million in 2025, then jumped by 959.37% to $80.3 million in 2026.
- Business Quant data shows ZBIO's Share-based Compensation at $80.3 million in Q1 2026, $7.6 million in Q4 2025, and $81.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | 8.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.62 Mn |
| Jun 30, 2026 | 8.62 Mn |
| Mar 31, 2026 | 80.30 Mn |
| Mar 31, 2026 | 80.30 Mn |
| Dec 31, 2025 | 7.58 Mn |
| Dec 31, 2025 | 7.58 Mn |
| Sep 30, 2025 | 81.20 Mn |
| Sep 30, 2025 | 81.20 Mn |
| Jun 30, 2025 | 6.05 Mn |
| Jun 30, 2025 | 6.05 Mn |
| Mar 31, 2025 | 5.39 Mn |
| Mar 31, 2025 | 5.39 Mn |
| Dec 31, 2024 | -4.23 Mn |
| Dec 31, 2024 | -4.23 Mn |
| Sep 30, 2024 | 2.84 Mn |
| Sep 30, 2024 | 2.84 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Mar 31, 2024 | 947,000.00 |
| Mar 31, 2024 | 947,000.00 |